Spitalul Clinic Judetean De Urgenta Cluj
- Address
- lock Available on a paid plan
Immunology and Rheumatology Research
At Spitalul Clinic Judetean De Urgenta Cluj, clinical trials in immune system processes and rheumatology focus on Systemic Lupus Erythematosus, a complex autoimmune disease that can cause widespread inflammation and organ involvement. The research is designed to assess whether new treatments can better control symptoms and improve long-term disease management for adults with active disease.
- Evaluating a new therapy for Systemic Lupus Erythematosus to improve signs and symptoms
- Assessing safety and overall treatment effectiveness in adults with moderate to severe disease
- Following patients over time to better understand long-term control of autoimmune activity
These studies reflect a strong interest in advancing care for inflammatory and autoimmune conditions, with an emphasis on safer and more effective options for patients living with SLE.
Metabolic Disease and Diabetes Studies
The site also supports research in nutritional and metabolic diseases, with a focus on type 2 diabetes. These trials aim to improve blood sugar control and support better treatment outcomes for people whose diabetes remains difficult to manage on standard therapy.
- Testing a new treatment approach for type 2 diabetes in people with inadequate glycaemic control
- Comparing blood sugar and weight outcomes against established diabetes therapies
- Exploring ways to strengthen routine diabetes care for patients using background treatment such as metformin
Research in this area combines metabolic health and treatment effectiveness, helping clarify whether newer options can offer meaningful benefits for people with diabetes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 94 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 91 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
- 1Novartis Pharma AG4active
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG12trials
lock +18 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic Judetean De Urgenta Cluj
lock Showing 1 of 92 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 94 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ianalumab | 5 | Unknown | 2022-07-14 | 2024-05-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.